Zogenix , Nasdaq: ZGNX
Recently launched Sumavel DosePro, a needle-free injectable migraine treatment.
Industry: Health Care
First Day Return: -0.5%
ZGNX
Recently launched Sumavel DosePro, a needle-free injectable migraine treatment.
| IPO Data | |
|---|---|
| IPO Date | 11/22/2010 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $56 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | San Diego, CA, United States |
| Founded | 2006 |
| Employees at IPO | 145 |
| Website www.zogenix.com | |
Zogenix (ZGNX) Performance
